Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I and Pharmacokinetic Study to Evaluate Histone Deacetylase Inhibitor, Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer

NCT02833155 is registered in ClinicalTrials.gov with Taizhou EOC Pharma Co., Ltd. as lead sponsor.

NCT NCT02833155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02833155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I and Pharmacokinetic Study to Evaluate Histone Deacetylase Inhibitor, Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer
Lead sponsor
Taizhou EOC Pharma Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
August 29, 2016
Completion date
July 18, 2018
Enrollment
19 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer